Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping.

bebtelovimab (LY-CoV1404) - AbCellera, Eli Lilly

bamlanivimab/etesevimab (LY-CoV555/LY-CoV016) - Eli Lilly

Xevudy (sotrovimab) - GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases

http://www.ncbi.nlm.nih.gov/pubmed/37828918

Hyun Goo Woo; Masaud Shah

Oct 13, 2023